PRECLINICAL TOXICOLOGY AND PHARMACOLOGY OF DRUGS DEVELOPED FOR CANCER, AIDS AND AIDS-RELATED ILLNESSES RELEASE DATE: June 23, 2003 NOTICE: NOT-CA-03-033 National Cancer Institute (NCI) (http://www.nci.nih.gov) The Developmental Therapeutics Program (DTP) of the Division of Cancer Treatment, Diagnosis and Centers (DCTD) of the National Cancer Institute (NCI) is seeking organizations to carry out pharmacology and toxicology studies, the data from which must be suitable for filing with the Food and Drug Administration as part of Investigational New Drug Applications. The organizations should have the facilities and staff to carry out such studies and the management expertise to analyze and evaluate the data. Proposals must meet the Mandatory Qualification Criterion at the time of submission of initial proposals. As a minimum requirement, the contractors must perform all toxicology studies in accord with the FDA's current Good Laboratory Practice Regulations (GLPs). Contractors must also indicate their willingness to sign a confidentiality of information statement. Multiple contracts will be awarded and each will be administered on a work assignment managed basis. Work assignments will be issued under the "funded cost- reimbursement completion" contracts resulting from this solicitation. Assignments are estimated to involve two to three chemical agents annually per contract. Offerors are required to propose two levels of effort (64,015 and 127,960 hours over a 7 year period). The objectives of the work assignments in relative order of importance are: 1) assessment of acute and subacute toxicity in rodents, dogs, non-human primates (NHPs) and other animal models including determination of a maximum tolerated dose (MTD), dose limiting toxicities (DLT), schedule- dependent toxicity, the reversibility of adverse effects and of a safe clinical starting dose; 2) validation of analytical methodology to quantitate plasma drug levels in preclinical animal models and to measure plasma drug levels in animal models treated with the agent under study; 3) determination of bioavailability of drug after parenteral and/or oral administration, if efficacious drug levels can be attained in plasma in vivo and if the drug crosses the blood-brain barrier; 4) the use of pharmacokinetic information to permit extrapolation of toxic effects across species by relating plasma drug levels to the time of appearance and severity of toxicity; and to establish the safety of potentially efficacious doses. The Principal Investigator should have a doctoral degree in pharmacology/ toxicology plus at least five years experience in directing, implementing, and evaluating drug toxicity studies in experimental animals. The Pathologist, Pharmacokineticist, and Analytical Chemist should likewise have credentials, which illustrate their competence and accomplishments in serving as critical team members in the conduct of such studies. The government anticipates multiple awards on an incremental funded basis. Each increment will be for one year and the total contract will be awarded for a seven year period on or about February 28, 2004. All responsive offers will be considered. The solicitation is scheduled for electronic release approximately July 17, 2003. The proposals will be due approximately 65 days following the actual date of RFP issuance. The RFP may be accessed through the Research Contracts Branch Home Page by using the following internet address: http://rcb.nci.nih.gov. It's the offeror's responsibility to monitor the above Internet site for the release of this solicitation and amendments, if any. Potential offerors will be responsible for downloading their own copy of the solicitation and amendments. No collect calls will be accepted. INQUIRIES For further information contact: Diane H. Stalder Contract Specialist Treatment, Biology, and Sciences Section, RCB 6120 Executive Blvd. Rockville, MD 20892-7193 Telephone: 301-435-3822 Fax: 301-402-6699 E-mail: ds88b@nih.gov
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, RealPlayer, Video or Flash files, see Help Downloading Files. |